INTERVENTION 1:	Intervention	0
FEC-75 Then Paclitaxel/Trastuzumab	Intervention	1
Patients receive Fluorouracil, epirubicin, and cyclophosphamide (FEC) comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies	Intervention	2
cyclophosphamide	CHEBI:4026	47-63
cyclophosphamide	CHEBI:4026	131-147
cyclophosphamide	CHEBI:4026	582-598
hydrochloride	CHEBI:36807	109-122
hydrochloride	CHEBI:36807	557-570
day	UO:0000033	154-157
day	UO:0000033	188-191
day	UO:0000033	221-224
paclitaxel	CHEBI:45863	268-278
paclitaxel	CHEBI:45863	386-396
paclitaxel	CHEBI:45863	610-620
surgery	OAE:0000067	431-438
surgery	OAE:0000067	466-473
surgery	OAE:0000067	680-687
surgery	OAE:0000067	697-704
biomarker	CHEBI:59163	717-726
INTERVENTION 2:	Intervention	3
Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75	Intervention	4
Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies	Intervention	5
paclitaxel	CHEBI:45863	17-27
paclitaxel	CHEBI:45863	129-139
paclitaxel	CHEBI:45863	602-612
cyclophosphamide	CHEBI:4026	225-241
cyclophosphamide	CHEBI:4026	574-590
day	UO:0000033	100-103
day	UO:0000033	248-251
day	UO:0000033	282-285
surgery	OAE:0000067	452-459
surgery	OAE:0000067	487-494
surgery	OAE:0000067	672-679
surgery	OAE:0000067	689-696
hydrochloride	CHEBI:36807	549-562
biomarker	CHEBI:59163	709-718
Inclusion Criteria:	Eligibility	0
Diagnosis of invasive adenocarcinoma by core needle biopsy	Eligibility	1
adenocarcinoma	DOID:299	22-36
Fine needle aspiration allowed provided primary tumor size < 2 cm and lymph node metastases are present	Eligibility	2
aspiration	HP:0002835	12-22
size	PATO:0000117	54-58
lymph	UBERON:0002391	70-75
present	PATO:0000467	96-103
Excisional biopsy of the primary tumor allowed provided biopsy-positive lymph nodes are present	Eligibility	3
lymph	UBERON:0002391	72-77
present	PATO:0000467	88-95
Primary tumor  2 cm and/or  1 biopsy-positive lymph node	Eligibility	4
lymph	UBERON:0002391	46-51
HER2-positive disease	Eligibility	5
disease	DOID:4,OGMS:0000031	14-21
Confirmation by fluorescent in situ hybridization (FISH) requires gene amplification	Eligibility	6
gene	BAO:0000582	66-70
Confirmation by immunohistochemistry (IHC) requires a strongly positive (3+) staining intensity score	Eligibility	7
immunohistochemistry	BAO:0000415	16-36
intensity	PATO:0000049	86-95
Ductal carcinoma in situ (DCIS) or synchronous DCIS of the contralateral breast regardless of prior therapy allowed	Eligibility	8
ductal carcinoma in situ	HP:0030075,DOID:0060074	0-24
breast	UBERON:0000310	73-79
Synchronous invasive breast cancer not allowed	Eligibility	9
breast cancer	DOID:1612	21-34
Ipsilateral DCIS treated by local excision with or without hormonal therapy allowed	Eligibility	10
Those treated with radiation therapy are not allowed	Eligibility	11
No definitive clinical or radiologic evidence of metastatic disease	Eligibility	12
disease	DOID:4,OGMS:0000031	60-67
No history of invasive breast cancer	Eligibility	13
history	BFO:0000182	3-10
breast cancer	DOID:1612	23-36
Hormone receptor status known	Eligibility	14
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
Menopausal status not specified	Eligibility	15
ECOG performance status of 0 -1	Eligibility	16
Absolute neutrophil count  1,200/mm³	Eligibility	17
Platelet count  100,000/mm³	Eligibility	18
platelet count	CMO:0000029	0-14
Total bilirubin normal unless the patient has a grade 1 bilirubin elevation (normal to 1.5 times upper limit of normal [ULN]) resulting from Gilbert disease or similar syndrome due to slow conjugation of bilirubin	Eligibility	19
patient	HADO:0000008,OAE:0001817	34-41
disease	DOID:4,OGMS:0000031	149-156
syndrome	DOID:225	168-176
Alkaline phosphatase  2.5 times ULN	Eligibility	20
phosphatase	GO:0016791,BAO:0000295	9-20
AST  1.5 times ULN	Eligibility	21
Creatinine normal	Eligibility	22
creatinine	CHEBI:16737	0-10
Left ventricular ejection fraction (LVEF)  55 by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) within the past 3 months	Eligibility	23
left	HP:0012835	0-4
ejection fraction	CMO:0000180	17-34
Patients with either skeletal pain or alkaline phosphatase that is > ULN but  2.5 times ULN allowed if bone scans fail to demonstrate metastatic disease	Eligibility	24
pain	HP:0012531	30-34
phosphatase	GO:0016791,BAO:0000295	47-58
disease	DOID:4,OGMS:0000031	145-152
Suspicious findings on bone scan must be confirmed as benign by x-ray, MRI, or biopsy	Eligibility	25
Prior non-breast malignancies allowed if disease-free for 5 years since completion of initial treatment regimen and deemed by their physician to be at low risk for recurrence	Eligibility	26
Patients who had the following cancers are eligible if diagnosed and treated within the past 5 years:	Eligibility	27
Carcinoma in situ of the cervix	Eligibility	28
carcinoma	HP:0030731,DOID:305	0-9
Colon carcinoma in situ	Eligibility	29
colon carcinoma in situ	DOID:8826	0-23
Melanoma in situ	Eligibility	30
melanoma	HP:0002861,DOID:1909	0-8
Basal cell and squamous cell carcinoma of the skin	Eligibility	31
squamous cell carcinoma of the skin	HP:0006739	15-50
No cardiac disease that would preclude the use of epirubicin hydrochloride or trastuzumab (Herceptin®) including any of the following:	Eligibility	32
disease	DOID:4,OGMS:0000031	11-18
hydrochloride	CHEBI:36807	61-74
Active cardiac disease	Eligibility	33
active	PATO:0002354	0-6
disease	DOID:4,OGMS:0000031	15-22
Angina pectoris that requires the use of antianginal medication	Eligibility	34
angina pectoris	HP:0001681	0-15
Cardiac arrhythmia requiring medication	Eligibility	35
arrhythmia	HP:0011675	8-18
Severe conduction abnormality	Eligibility	36
severe	HP:0012828	0-6
Clinically significant valvular disease	Eligibility	37
disease	DOID:4,OGMS:0000031	32-39
Cardiomegaly on chest x-ray	Eligibility	38
cardiomegaly	HP:0001640	0-12
chest	UBERON:0001443	16-21
Ventricular hypertrophy on EKG	Eligibility	39
ventricular hypertrophy	HP:0001714	0-23
Patient's with poorly controlled hypertension ( i.e., diastolic greater than 100 mm/Hg)	Eligibility	40
patient	HADO:0000008,OAE:0001817	0-7
hypertension	HP:0000822,DOID:10763	33-45
Patients with hypertension that is well controlled on medication are eligible	Eligibility	41
hypertension	HP:0000822,DOID:10763	14-26
History of cardiac disease	Eligibility	42
history	BFO:0000182	0-7
disease	DOID:4,OGMS:0000031	19-26
Myocardial infarction documented as a clinical diagnosis or by EKG or any other tests	Eligibility	43
myocardial infarction	HP:0001658,DOID:5844	0-21
Documented congestive heart failure	Eligibility	44
congestive heart failure	HP:0001635,DOID:6000	11-35
Documented cardiomyopathy	Eligibility	45
cardiomyopathy	HP:0001638,DOID:0050700	11-25
No sensory or motor neuropathy  grade 2, as defined by the NCI's CTCAE v3.0	Eligibility	46
neuropathy	DOID:870	20-30
Women of reproductive potential must agree to use an effective non-hormonal method of contraception during therapy	Eligibility	47
Women of child bearing potential must have a negative urine or serum pregnancy test within 2 weeks of registration	Eligibility	48
urine	UBERON:0001088	54-59
Not pregnant or nursing	Eligibility	49
No psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements	Eligibility	50
patient	HADO:0000008,OAE:0001817	119-126
No non-malignant systemic disease (e.g., cardiovascular, renal, hepatic) that would preclude treatment with either of the treatment regimens	Eligibility	51
disease	DOID:4,OGMS:0000031	26-33
No prior surgical axillary staging procedure	Eligibility	52
Prior non-excisional biopsy of an axillary node allowed	Eligibility	53
No prior treatment for this breast cancer	Eligibility	54
breast cancer	DOID:1612	28-41
Hormonal therapy allowed if had been given for up to a total of 28 days anytime after diagnosis and before study entry	Eligibility	55
Hormonal therapy must stop at or before study entry and be re-started, if indicated, following surgery	Eligibility	56
surgery	OAE:0000067	95-102
No prior therapy with anthracyclines or taxanes for any malignancy	Eligibility	57
No other investigational agents within the past 30 days	Eligibility	58
No concurrent sex hormonal therapy (e.g., birth control pills, ovarian hormonal replacement therapy)	Eligibility	59
No concurrent therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulator (SERM), either for osteoporosis or breast cancer prevention	Eligibility	60
raloxifene	CHEBI:8772	54-64
tamoxifen	CHEBI:41774	66-75
estrogen receptor modulator	CHEBI:50739	96-123
osteoporosis	HP:0000939,DOID:11476	143-155
breast cancer	DOID:1612	159-172
Outcome Measurement:	Results	0
pCR Within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy	Results	1
breast	UBERON:0000310	15-21
breast	UBERON:0000310	81-87
surgery	OAE:0000067	91-98
Pathological complete response (pCR) rates will be based on institutional pathology reports. In the final analysis for publication, rates will be based on blinded central review of these institutional pathology reports. The Chi-squared test will be conducted at the two-sided 0.05 level. A 95% confidence interval will be computed for the difference in pCR rates.	Results	2
central	HP:0030645	163-170
Time frame: Up to 5 years	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: FEC-75 Then Paclitaxel/Trastuzumab	Results	5
Arm/Group Description: Patients receive Fluorouracil, epirubicin, and cyclophosphamide (FEC) comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies	Results	6
cyclophosphamide	CHEBI:4026	70-86
cyclophosphamide	CHEBI:4026	154-170
cyclophosphamide	CHEBI:4026	605-621
hydrochloride	CHEBI:36807	132-145
hydrochloride	CHEBI:36807	580-593
day	UO:0000033	177-180
day	UO:0000033	211-214
day	UO:0000033	244-247
paclitaxel	CHEBI:45863	291-301
paclitaxel	CHEBI:45863	409-419
paclitaxel	CHEBI:45863	633-643
surgery	OAE:0000067	454-461
surgery	OAE:0000067	489-496
surgery	OAE:0000067	703-710
surgery	OAE:0000067	720-727
biomarker	CHEBI:59163	740-749
Overall Number of Participants Analyzed: 138	Results	7
Measure Type: Number	Results	8
Unit of Measure: percentage of participants  56.5        (47.8 to 64.9)	Results	9
Results 2:	Results	10
Arm/Group Title: Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75	Results	11
Arm/Group Description: Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies	Results	12
paclitaxel	CHEBI:45863	40-50
paclitaxel	CHEBI:45863	152-162
paclitaxel	CHEBI:45863	625-635
cyclophosphamide	CHEBI:4026	248-264
cyclophosphamide	CHEBI:4026	597-613
day	UO:0000033	123-126
day	UO:0000033	271-274
day	UO:0000033	305-308
surgery	OAE:0000067	475-482
surgery	OAE:0000067	510-517
surgery	OAE:0000067	695-702
surgery	OAE:0000067	712-719
hydrochloride	CHEBI:36807	572-585
biomarker	CHEBI:59163	732-741
Overall Number of Participants Analyzed: 142	Results	13
Measure Type: Number	Results	14
Unit of Measure: percentage of participants  54.2        (45.7 to 62.6)	Results	15
Adverse Events 1:	Adverse Events	0
Total: 19/138 (13.77%)	Adverse Events	1
Blood disorder 1/138 (0.72%)	Adverse Events	2
blood	UBERON:0000178	0-5
disorder	OGMS:0000045	6-14
Febrile neutropenia 1/138 (0.72%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	8-19
Hemoglobin decreased 8/138 (5.80%)	Adverse Events	4
hemoglobin	CHEBI:35143	0-10
Hemolysis 0/138 (0.00%)	Adverse Events	5
Atrial fibrillation 0/138 (0.00%)	Adverse Events	6
atrial fibrillation	HP:0005110,DOID:0060224	0-19
Left ventricular failure 3/138 (2.17%)	Adverse Events	7
left	HP:0012835	0-4
Myocardial ischemia 0/138 (0.00%)	Adverse Events	8
ischemia	DOID:326	11-19
Sinus tachycardia 1/138 (0.72%)	Adverse Events	9
sinus tachycardia	HP:0011703	0-17
Supraventricular tachycardia 0/138 (0.00%)	Adverse Events	10
supraventricular tachycardia	HP:0004755	0-28
Extraocular muscle paresis 0/138 (0.00%)	Adverse Events	11
Adverse Events 2:	Adverse Events	12
Total: 26/142 (18.31%)	Adverse Events	13
Blood disorder 1/142 (0.70%)	Adverse Events	14
blood	UBERON:0000178	0-5
disorder	OGMS:0000045	6-14
Febrile neutropenia 3/142 (2.11%)	Adverse Events	15
neutropenia	HP:0001875,DOID:1227	8-19
Hemoglobin decreased 11/142 (7.75%)	Adverse Events	16
hemoglobin	CHEBI:35143	0-10
Hemolysis 1/142 (0.70%)	Adverse Events	17
Atrial fibrillation 1/142 (0.70%)	Adverse Events	18
atrial fibrillation	HP:0005110,DOID:0060224	0-19
Left ventricular failure 5/142 (3.52%)	Adverse Events	19
left	HP:0012835	0-4
Myocardial ischemia 1/142 (0.70%)	Adverse Events	20
ischemia	DOID:326	11-19
Sinus tachycardia 1/142 (0.70%)	Adverse Events	21
sinus tachycardia	HP:0011703	0-17
Supraventricular tachycardia 1/142 (0.70%)	Adverse Events	22
supraventricular tachycardia	HP:0004755	0-28
Extraocular muscle paresis 1/142 (0.70%)	Adverse Events	23
